Comparing Neoadjuvant FOLFOXIRI Versus CAPOXFOLFOX Chemotherapy with Chemoradiotherapy Followed by Surgery or Watch-and-Wait in High-Risk Locally Advanced Rectal Cancer
Led by J. W. A. Burger · Updated on 2026-10-27
394
Participants Needed
20
Research Sites
208 weeks
Total Duration
AI-Summary
What This Trial Is About
The trial investigates treatments for patients with high-risk locally advanced rectal cancer. It compares triplet induction chemotherapy FOLFOXIRI with doublet induction chemotherapy CAPOXFOLFOX, both followed by chemoradiotherapy and then either surgery or a watch-and-wait approach. The study aims to find out if the triplet therapy leads to higher complete response rates, better quality of life, and improved long-term outcomes despite a potential increase in side effects.
Participants in one group receive FOLFOXIRI chemotherapy given in cycles every two weeks, followed by chemoradiotherapy that includes radiation combined with capecitabine or an alternative drug if needed. The other group receives CAPOX or FOLFOX chemotherapy followed by the same chemoradiotherapy regimen. After these treatments, patients either have surgery or enter a watch-and-wait follow-up if their cancer shows complete response. Imaging scans are done at multiple points to evaluate treatment response, and surgery timing depends on these results.
During the study, participants undergo regular imaging with MRI and CT scans, endoscopies, and clinical exams to assess tumor response. Quality of life and work productivity questionnaires are completed at baseline and after treatments. Researchers monitor treatment toxicity, dose adjustments, surgical outcomes, and long-term survival and recurrence over several years. Follow-up includes close monitoring for tumor regrowth or recurrence, especially for those in the watch-and-wait group, with visits scheduled up to five years after treatment.
CONDITIONS
Brief Title
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer
Research Team
M
Maaike M Borg, Drs.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
ZonMw: The Netherlands Organisation for Health Research and Development
Collaborating Sponsor
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Age 18 years or older
WHO performance status of 0 or 1
Fit for modified dose triple chemotherapy (FOLFOXIRI)
Histologically confirmed rectal cancer with tumor located at or below the sigmoidal take-off on pelvic MRI
High-risk locally advanced rectal cancer with at least one of these imaging features: cT4b tumor or mesorectal fascia invasion within 0 mm plus thickening over 5 mm, grade 4 extramural venous invasion, tumor deposits, or bilateral/extensive enlarged lateral lymph nodes
Resectable disease determined by MRI or after neoadjuvant treatment
Provided written informed consent
You will not qualify if you...
Evidence of metastatic disease at or within six months before inclusion, except for enlarged iliac or inguinal lymph nodes and nonspecific lung nodules
Homozygous DPD enzyme deficiency
Chemotherapy within the past 6 months
Contraindications to planned systemic therapy such as severe allergy, pregnancy, kidney problems, or low platelet count
Previous pelvic radiotherapy preventing chemoradiotherapy at prescribed doses
Contraindications to planned chemoradiotherapy including allergy or inability to receive radiation
Contraindications to surgery as determined by surgeon or anesthesiologist
Other malignancies interfering with study treatment or prognosis
Microsatellite instability (MSI)
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are assessed for eligibility based on medical history, imaging, and health status to determine if they meet the study requirements.
1 to 2 visits
Induction Chemotherapy
Duration - Approximately 12 to 14 weeks
Participants receive either FOLFOXIRI or CAPOX/FOLFOX chemotherapy cycles over several weeks. Imaging is performed to evaluate tumor response after initial cycles.
Multiple visits during chemotherapy cycles
Chemoradiotherapy
Duration - Approximately 5 weeks
Following chemotherapy, participants undergo chemoradiotherapy with radiation and oral chemotherapy for about 5 weeks.
Daily radiotherapy visits over 25 days
Restaging and Surgery or Watch-and-Wait
Duration - Up to 16 weeks after chemoradiotherapy
Participants are restaged with imaging and endoscopy to assess tumor response. Those with incomplete response undergo surgery within 10 to 14 weeks after chemoradiotherapy, while those with complete response may enter a watch-and-wait follow-up approach.
Several imaging and clinical visits during restaging and surgery
Long-term Follow-up
Duration - Up to 5 years
Participants are monitored closely for tumor regrowth or recurrence with regular imaging and examinations up to 5 years after treatment. Quality of life and other outcomes are also assessed.
Follow-up visits every 3 months in year 1, then every 6 months in year 2, and every 6 to 12 months in years 3 to 5
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Study Comparing Chemoradiotherapy With and Without Tislelizumab for Treating Locally Advanced Rectal Cancer
Using Circulating Tumor DNA to Guide Neoadjuvant Treatment for Locally Advanced Rectal Cancer
A Phase 2 Multicenter Randomized Controlled Trial
Feasibility Study of Supervised Aerobic and Resistance Exercise to Enhance Chemoradiotherapy in Adults with Locally Advanced Rectal Cancer
Phase 3 Study of Adding Modulated Electro-Hyperthermia to Standard Total Neoadjuvant Therapy for Adults with Locally Advanced Rectal Cancer
Comparing Neoadjuvant FOLFOXIRI Versus CAPOXFOLFOX Chemotherapy with Chemoradiotherapy Followed by Surgery or Watch-and-Wait in High-Risk Locally Advanced Rectal Cancer
Study Comparing Contact X-ray Brachytherapy Versus Waiting Longer and Local Excision for Preserving the Rectum in Patients With Good Response After Chemoradiation for Rectal Cancer
Phase 2 Study of Serplulimab with CAPEOX and Celecoxib as Pre-Surgery Treatment for Locally Advanced Rectal Cancer
Evaluating Short Course Radiation and Combination Chemotherapy for Stage II-III Rectal Cancer to Preserve Organs and Improve Outcomes
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A national, multicentre, randomised, controlled, parallel-arms, phase III clinical trial of neoadjuvant FOLFOXIRI and chemoradiotherapy versus neoadjuvant CAPOX/FOLFOX and chemoradiotherapy in patients with high-risk locally advanced rectal cancer: study protocol of the MEND-IT II trial.